RH1 (NSC 697726) is a potent bioreductive agent with significant anticancer activity both in vitro and in vivo; it induces DNA cross-linking and apoptosis in NQ16 cells in a time- and concentration-dependent manner; it exhibits dose-dependent antitumor activity against NQ16 tumors in athymic mice, significantly reducing tumor volume at doses of 0.4 mg/kg, 0.2 mg/kg, and even 0.1 mg/kg compared to controls.